Estela Rodriguez/X
Feb 9, 2025, 05:06
Estela Rodriguez: A new option for a small subgroup of lung adenocarcinoma approved by FDA
Estela Rodriguez, Associate Director of Community Outreach and Co-Lead of the Thoracic Site Disease Group of the Sylvester Comprehensive Cancer Center, shared a post on X:
“Already approved by FDA Oncology. Zenocutuzumab in NRG1+Fusion-Positive Cancer.
A new option for a small subgroup of lung adenocarcinoma (0.2%)- if you test you could find it. | via NEJM.”
Efficacy of Zenocutuzumab in NRG1 Fusion-Positive Cancer
Authors: Alison M. Schram et al.
Alexander Drilon
Alison M. Schram
Andrew K. Joe
Antoine Hollebecque
Benjamin A. Weinberg
Christoph Springfeld
Cindy Neuzillet
Dong-Wan Kim
Eileen M. O'Reilly
Emiliano Calvo
Ernesto Wasserman
Frans Opdam
Grainne M. O'Kane
James M. Cleary
Jim Ford
Joon Oh Park
Jordi Rodon
Kazumi Nishino
Kim A. Reiss
Koichi Goto
Kumiko Umemoto
Lokesh Jain
M.S.
Michael Duruisseaux
Misako Nagasaka
Sai-Hong Ignatius Ou
Shekeab Jauhari
Shola Adeyemi
Stephen V Liu
Sun Young Rha
Tanios Bekaii-Saab
Teresa Macarulla
Viktoriya Stalbovskaya
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Feb 9, 2025, 14:06
Feb 9, 2025, 13:58
Feb 9, 2025, 13:28
Feb 9, 2025, 13:23
Feb 9, 2025, 12:28
Feb 9, 2025, 04:51
Feb 9, 2025, 04:49